Based out of Nijmegen, The Netherlands, Enzyre is a spin-out from Radboud University Medical Center, developing Enzypad, a near-patient diagnostic and monitoring device initially focused on blood coagulation.
Raised €1.4M Corona Bridge Loan
In the latest development, Enzyre secured €1.4M Corona Bridge Loan granted by the Dutch government in support of innovative startups and scaleups. Novalis Biotechnology Incubation that provides seed funding and ongoing support to biotechnology and life sciences companies also participated in the funding round.
Dirk Pollet, CEO of Enzyre commented: “We are pleased to welcome Novalis Biotechnology Incubation to our investor base. The Novalis team is very well aligned with Enzyre’s strategy to “bring the laboratory to the patient”, enabling them to avoid hospital visits. We firmly believe there is a huge demand for technology that empowers patients and allows healthcare workers to provide the best therapy without delay and increased cost. Enzypad can meet this demand.“
The first application of Enzypad will revolutionize monitoring of hemophilia by providing a real-time picture of a patient’s blood coagulation status. The result of each test made by a patient is sent automatically to the treating physicians through an app on a mobile phone.
Growing need for NPT tools
Right now, there is a growing need for NPT (Near Patient Test) tools, which offer patients and healthcare workers the possibility for remote personalized and data-based disease management via telemedicine, avoiding hospital visits and reducing healthcare costs.
Enzyre’s platform technology is unique as it requires just a small volume of blood and can measure up to twelve (12) biomarkers simultaneously without any laboratory infrastructure; at home, on the road, or in a critical care setting.
Small hand-held diagnostic tool
Furthermore, Enzyre’s proprietary technology is a small hand-held diagnostic tool using disease-specific single-use microfluidic cartridges with high sensitivity and specificity. It has broad applicability in several disease areas.
In December 2019, Enzyre signed a collaboration with Takeda for the development of Enzypad in congenital bleeding disorders, validating this innovative approach.
Prof. Wim Van Criekinge, co-founder of Novalis added: “Near patient testing presents a major opportunity in today’s world to obtain an improved treatment outcome for patients. More and better data is an essential element in our drive to advance healthcare. We were impressed by the Enzyre team and Enzypad technology, which has many application areas beyond coagulation testing. Our investment in Enzyre perfectly matches our strategy of investing in innovative breakthrough technology in life sciences.”
Main image credits: Enzyre